Mini Review
Volume 5 Issue 6 - 2021
Hepatic First Pass Metabolism: The Implication on the Biological Activity of Atypical Antipsychotic Agents
Chika J Mbah*
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, Nigeria
*Corresponding Author: Chika J Mbah, Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, Nigeria.
Received: May 24, 2021; Published: May 31, 2021




Abstract

Hepatic first pass metabolism is the metabolism of a drug in the liver received through the portal circulation prior to reaching systemic circulation. The liver is the principal organ of first pass metabolism in the body and has blood flow of about 20 - 25% of the total cardiac output. The objective of the study was to ascertain the effects of hepatic first pass metabolism on the biological activity of atypical antipsychotic agents. Scientific journals, official books and internet websites were the sources of the information. The results show amisulpride, aripiprazole, asenapine, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone and ziprasidone to be the atypical antipsychotic agents. Some of them were found to undergo significant hepatic first pass metabolism. Poor bioavailability was observed with some of these atypical antipsychotics due to hepatic first pass metabolism. The therapeutic outcomes of orally administered atypical antipsychotic agents depict that there are relationships between threshold plasma drug levels and clinical responses. In summary, hepatic first pass metabolism has no drawbacks on the biological activity of clinically used atypical antipsychotic agents.

Keywords: Hepatic First Pass Metabolism; Atypical Antipsychotics; Biological Activity

References

  1. Sloss A. “Prescribing in liver disease”. Australia Prescriber2 (2009): 32-35.
  2. Vasanthkumar T., et al. “Hepatoprotective effect of curcumin and capsaicin against lipopolysaccharide induced liver damage in mice”. Pharmacognosy Journal6 (2017): 947-951.
  3. Derendorf H., et al. “Pharmacokinetics and oral bioavailability of hydrocortisone”. Journal Clinical Pharmacology 31 (1991): 473-476.
  4. Dresser GK., et al. “Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition”. Clinical Pharmacokinetic 38 (2000): 41-57.
  5. Reed MD., et al. “The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration”. Journal Clinical Pharmacology 12 (2001) 1359-1363.
  6. Kim J., et al. “Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process”. International Journal Pharmaceutics 1-2 (2008): 211-219.
  7. Antignac M., et al. “Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients” British Journal Clinical Pharmacology6 (2007): 750-757.
  8. Sanders SW., et al. “Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing”. European Journal Clinical Pharmacology 3 (1986): 331-334.
  9. Shargel L and Yu AB. “Applied biopharmaceutics and pharmacokinetics”, 4th edition, McGraw-Hill, New York (1999).
  10. Leucht S., et al. “New generation antipsychotics versus low-potency conventional antipsychotics”: a systematic review and meta-analysis”. Lancet 361 (2003): 1581-1589.
  11. Bymaster FP., et al. “Radioreceptor binding profile of the atypical antipsychotic olanzapine”. Neuropsychopharmacology 14 (1996): 87-96.
  12. Mauri MC., et al. “Clinical pharmacology of atypical antipsychotics”: An update: EXCLI Journal 13 (2014): 1163-1191.
  13. Seeman P. “Atypical antipsychotics: mechanism of action”. Canadian Journal Psychiatry 47 (2002): 27-38.
  14. Miyamoto S., et al. “Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs”. Molecular Psychiatry 10 (2005): 79-104.
  15. Horacek J., et al. “Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia”. CNS Drugs 20 (2006): 389-409.
  16. Rosenzweig P., et al. “A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers”. Human Psychopharmacology 17 (2002): 1-13.
  17. Jordan S., et al. “The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor”. European Journal Pharmacology 441 (2002): 137-140.
  18. Winans E. “Aripiprazole”. American Journal Health System Pharmaceutics 60 (2003): 2437-2445.
  19. Citrome L. “Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism”. Expert Opinion on Drug Metabolism and Toxicology 10 (2014): 893-903.
  20. Jann MW., et al. “Pharmacokinetics and pharmacodynamics of clozapine”. Clinical Pharmacokinetic 24 (1993): 161-176.
  21. Rado JT and Janicak PG. “Long-term efficacy and safety of iloperidone: an update”. Neuropsychiatry Disposition Treatment 10 (2014): 409-415.
  22. Dinesh SP., et al. “LC–MS/MS assay for olanzapine in human plasma and its application to a bioequivalence study”. Acta Pharmaceutica Sinica B5 (2012): 481-494.
  23. Citrome L. “Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability”. Expert Opinion on Drug Metabolism and Toxicology 8 (2012a): 873-888.
  24. Grimm SW., et al. “In vitro prediction of potential metabolic drug interaction for seroquel”. Schizophrenia Research 24 (1997): 198-201.
  25. Mannens G., et al. “Absorption, metabolism, and excretion of risperidone in humans”. Drug Metabolism Disposition 21 (1993): 1134-1141.
  26. Stimmel GL., et al. “Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia”. Clinical Therapeutic 24 (2002): 21-37.
  27. Kronig MH., et al. “Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients”. American Journal Psychiatry 152 (1995): 179-182.
  28. Mauri MC., et al. “Clinical outcome and olanzapine plasma levels in acute schizophrenia”. European Psychiatry 20 (2005): 55-60.
  29. Khan AY and Preskorn SH. “Examining concentration dependence toxicity of clozapine: role of therapeutic drug monitoring”. Journal Psychiatry Practice 11 (2005): 289-301.
  30. Mauri MC., et al. “Clinical pharmacokinetics of atypical antipsychotics. A critical review of the relationship between plasma concentrations and clinical response”. Clinical Pharmacokinetic 46 (2007a): 359-388.
Citation: Chika J Mbah. “Hepatic First Pass Metabolism: The Implication on the Biological Activity of Atypical Antipsychotic Agents”. EC Emergency Medicine and Critical Care 5.6 (2021): 100-104.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


October Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the October issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before November 04, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk